XHKG
1349
Market cap110mUSD
Oct 09, Last price
2.55HKD
1D
0.00%
1Q
4.94%
Jan 2017
-60.65%
IPO
240.00%
Name
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PFC Device Inc., along with its subsidiaries, focuses on the innovation, design, production, and distribution of power discrete semiconductors, which are sold under its proprietary PFC brand. Its market reach extends throughout China, Hong Kong, Taiwan, and other Asian territories. The company's diverse product range includes rectifiers, MOSFETs, IGBTs, bridge rectifiers, and various packaging solutions, serving critical applications in general power systems, consumer electronics, industrial machinery, and the automotive sector. Additionally, PFC Device Inc. supplies power supply units, specialized packaging for mobile phone chargers, and power management solutions for network and communication infrastructure. The company also undertakes investment activities and holds trademarks. Founded in 2016, PFC Device Inc. is headquartered in Chai Wan, Hong Kong, and operates as a subsidiary of Lotus Atlantic Limited.
Key people
Yan Xue
Chief Financial Officer, Secretary of the Board, Director · since 2023
Xiaowen Li
General Manager · since 2021
Yu Chen
Deputy General Manager · since 2014
Jun Li
Deputy General Manager
Daiqing Yu
Deputy General Manager · since 2016
Dajun Zhao
Deputy General Manager, Executive Director · since 2020
Yanan Qu
Employee Director · since 2025
Non-Executive Director · since 2012
Xiaoyang Yu
Non-Executive Director · since 2013
Independent Non-Executive Director · since 2023
Hongguang Wang
Independent Non-Executive Director · since 2023
Peilong Xu
Independent Non-Executive Director · since 2023
Headquarters & legal address
区上海市浦东新区张江高科技园区蔡伦路308号
浦东新区, SH 100000
CN
浦东新区, SH 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||